Tezosentan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tezosentan
Tezosentan.png
Space-filling model of the tezosentan molecule
Systematic (IUPAC) name
N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide
Identifiers
CAS Registry Number 180384-57-0 YesY
ATC code None
PubChem CID: 151174
ChemSpider 133242 YesY
UNII 64J9J55263 YesY
ChEMBL CHEMBL61780 YesY
Chemical data
Formula C27H27N9O6S
Molecular mass 605.624
 YesY (what is this?)  (verify)

Tezosentan is a non-selective ETA and ETB receptor antagonist.[1] It acts as a vasodilator and was designed as a therapy for patients with acute heart failure. Recent studies have shown however, that tezosentan does not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.[2]

References[edit]

  1. ^ Urbanowicz, W; Sogni, P; Moreau, R; Tazi, K A; Barriere, E; Poirel, O; Martin, A; Guimont, M C; Cazals-Hatem, D; Lebrec, D (2004). "Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats". Gut (BMJ Publishing Group Ltd & British Society of Gastroenterology) 53 (12): 1844–1849. doi:10.1136/gut.2003.036517. PMC 1774327. PMID 15542526. 
  2. ^ "Tezosentan does not appear to improve symptoms for patients with acute heart failure". Medical Studies/Trials. news-medical.net. 7 Nov 2007. Retrieved 2007-11-24.